Trial Profile
Phase II trial of DX 2930 in patients with hereditary angioedema.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2015
Price :
$35
*
At a glance
- Drugs Lanadelumab (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Sponsors Dyax
- 24 Feb 2015 According to a Dyax media release, this trial is expected to start in the second half of 2015.
- 10 Nov 2014 New trial record